1. Martin J, Chung P, Warde P. Treatment options, prognostic factors and selection of treatment in stage I seminoma. Onkologie. 2006;29(12):592–8.
2. Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodore C. Advanced seminoma – treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer. 2003;98(4):745–52.
3. Angulo JC, González J, Rodríguez N, Hernández E, Núñez C, Rodríguez-Barbero JM, et al. Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms). J Urol. 2009;182(5):2303–10.
4. Sinclair S, Swain SM. Primary systemic chemotherapy for inflammatory breast cancer. Cancer. 2010;116(11 Suppl l):2821–8.
5. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91.